suzhou, china, june 18, 2019 – alphamab oncology announced that kn046, an innovative pd-l1/ctla-4 bispecific antibody developed by the company has made new progress. the phase ib/ii clinical trial for kn046’s third indication of triple-negative breast cancer (tnbc) (study number: kn026-203) has been initiated by clinical centers at cancer hospital chinese academy of medical sciences, harbin medical university cancer hospital and hunan cancer hospital.
about kn046kn046 is the world's first recombinant humanized pd-l1/ctla-4 bispecific antibody independently developed by alphamab oncology. it simultaneously targets two important validated immunoregulatory targets thus activating tumor targeting t cells more effectively . kn046 will be developed for multiple types of malignancies such as gi cancer, lung cancer and breast cancer. results of phase i clinical trials conducted in australia and china have shown preliminary good safety and efficacy. phase ii clinical trials for nsclc and esophageal cancer have been launched in china recently.
alphamab oncology is a leading biopharmaceutical company in china dedicated to the development of innovative biologics for cancer therapy globally. so far, four drug candidates in alphamab oncology's pipeline have advanced into clinical development phase. with multiple in-house proprietary platforms for innovative biopharmaceuticals, alphamab oncology has built a robust pipeline in oncology/immunology to benefit cancer patients around the world.
please feel free to visit the official website: http://www.alphamabonc.com
fengzhang guan, 86-512-62850800 extension 8807